The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome
- 31 Downloads
Guillain-Barré syndrome (GBS) is a common acute immune-mediated inflammatory disorder affecting the peripheral nervous system (PNS) of humans. Studies in humans and in animal models revealed that neuropeptide Y (NPY) levels are altered in some neurodegenerative and neuroimmune disorders. Herein, we investigated the levels of NPY and cytokines in the serum of GBS patients and explored the roles of NPY in the disease severity and its short-term prognosis.
Twenty patients with GBS (case group) and twenty healthy individuals (control group) were enrolled in this study. NPY levels were analyzed by enzyme-linked immunosorbent assay (ELISA). The levels of pro- and anti-inflammatory cytokines (including interferon-γ (IFN-γ), interleukin (IL)-4, IL-10, IL-12p70, IL-17A, and tumor necrosis factor-α (TNF-α)) were analyzed using cytometric beads array (CBA). The clinical characteristics, disease severity, and short-term prognosis were compared between the two groups.
Compared with the control group, the levels of NPY and cytokines were significantly increased in the serum of patients with GBS. NPY levels in the serum of GBS patients were correlated with the disease severity.
Our results suggest that NPY and cytokines are involved in the pathogenesis of GBS. The levels of NPY can help to predict the severity of the disease.
KeywordsGuillain-Barré syndrome Neuropeptide Y Cytokines Disease severity Short-term prognosis
Peripheral nervous system
Enzyme-linked immunosorbent assay
Tumor necrosis factor-α
Cytometric beads array
Central nervous system
Hughes Functional Grading Scale
Medical Research Council
Statistical Product and Service Solutions
Experimental autoimmune neuritis
Helper T cell
Transforming growth factor β
This study was supported by grants from The First Hospital, Jilin University Changchun, China General Program of the National Natural Science Foundation (No. 81771299).
Compliance with ethical standards
This study was approved by the ethics committee of the First Hospital of Jilin University, Changchun, China.
Conflict of interest
The authors declare that they have no conflicts of interest.
Informed consent was obtained from all individual participants included in the study.
- 2.Ziganshin RH, Ivanova OM, Lomakin YA, Belogurov AA Jr, Kovalchuk SI, Azarkin IV, Arapidi GP, Anikanov NA, Shender VO, Piradov MA, Suponeva NA, Vorobyeva AA, Gabibov AG, Ivanov VT, Govorun VM (2016) The pathogenesis of the demyelinating form of Guillain-Barre Syndrome (GBS): proteo-peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics 15(7):2366–2378CrossRefGoogle Scholar
- 6.Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, Beck-Sickinger A, von Hörsten S, Yamamura T (2003) Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 171(7):3451–3458CrossRefGoogle Scholar